PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Gross profit growth exceeding 1.5x Biotechnology median of 19.02%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
-1.47%
Negative EBIT growth while Biotechnology median is 2.34%. Seth Klarman would check if external or internal factors caused the decline.
-1.47%
Negative operating income growth while Biotechnology median is 2.18%. Seth Klarman would check if structural or cyclical issues are at play.
-1.89%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
2.63%
EPS growth 50-75% of Biotechnology median of 3.90%. Guy Spier might worry about subpar cost control or limited growth levers.
2.63%
Diluted EPS growth 50-75% of Biotechnology median of 3.90%. Guy Spier might be concerned about partial underperformance or higher dilution.
3.22%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
3.22%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-50.21%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
91.36%
OCF/share CAGR of 91.36% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
62.52%
5Y OCF/share growth exceeding 1.5x Biotechnology median of 16.33%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
-48.56%
Negative 3Y OCF/share CAGR while Biotechnology median is 18.41%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
94.18%
Net income/share CAGR exceeding 1.5x Biotechnology median of 20.06% over a decade. Joel Greenblatt might see a standout compounder of earnings.
69.28%
5Y net income/share CAGR > 1.5x Biotechnology median of 29.50%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-24.85%
Negative 3Y CAGR while Biotechnology median is 23.67%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-50.75%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-32.62%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-67.01%
Negative 3Y equity/share growth while Biotechnology median is -55.24%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-15.55%
Negative BV/share change while Biotechnology median is -10.23%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-7.46%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
10.75%
R&D growth of 10.75% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-21.32%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.